JPWO2021262909A5 - - Google Patents
Info
- Publication number
- JPWO2021262909A5 JPWO2021262909A5 JP2022579691A JP2022579691A JPWO2021262909A5 JP WO2021262909 A5 JPWO2021262909 A5 JP WO2021262909A5 JP 2022579691 A JP2022579691 A JP 2022579691A JP 2022579691 A JP2022579691 A JP 2022579691A JP WO2021262909 A5 JPWO2021262909 A5 JP WO2021262909A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063042822P | 2020-06-23 | 2020-06-23 | |
US63/042,822 | 2020-06-23 | ||
US202163165094P | 2021-03-23 | 2021-03-23 | |
US63/165,094 | 2021-03-23 | ||
US202163165469P | 2021-03-24 | 2021-03-24 | |
US63/165,469 | 2021-03-24 | ||
PCT/US2021/038780 WO2021262909A2 (en) | 2020-06-23 | 2021-06-23 | Lnp compositions comprising mrna therapeutics with extended half-life |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023531511A JP2023531511A (ja) | 2023-07-24 |
JPWO2021262909A5 true JPWO2021262909A5 (de) | 2024-07-01 |
Family
ID=77155849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022579691A Pending JP2023531511A (ja) | 2020-06-23 | 2021-06-23 | 半減期が延長されたmRNA治療薬を含むLNP組成物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230242908A1 (de) |
EP (1) | EP4168556A2 (de) |
JP (1) | JP2023531511A (de) |
KR (1) | KR20230042005A (de) |
CN (1) | CN116194151A (de) |
AU (1) | AU2021297248A1 (de) |
BR (1) | BR112022025991A2 (de) |
CA (1) | CA3187261A1 (de) |
IL (1) | IL299196A (de) |
MX (1) | MX2022016550A (de) |
WO (1) | WO2021262909A2 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023183550A2 (en) * | 2022-03-25 | 2023-09-28 | Modernatx, Inc. | Messenger ribonucleic acids with extended half-life |
WO2023183909A2 (en) * | 2022-03-25 | 2023-09-28 | Modernatx, Inc. | Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia |
WO2023196399A1 (en) * | 2022-04-06 | 2023-10-12 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria |
WO2023215498A2 (en) * | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8613481D0 (en) | 1986-06-04 | 1986-07-09 | Diatech Ltd | Translation of mrna |
US5723332A (en) | 1993-11-26 | 1998-03-03 | British Technology Group Limited | Translational enhancer DNA |
US5824497A (en) | 1995-02-10 | 1998-10-20 | Mcmaster University | High efficiency translation of mRNA molecules |
EP2428569B1 (de) | 2001-09-28 | 2018-05-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Mikrorna-moleküle |
US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
KR101541935B1 (ko) | 2007-09-26 | 2015-08-05 | 인트렉손 코포레이션 | 합성 5'utr, 발현 벡터, 및 전이유전자 발현의 증가방법 |
CA3013503A1 (en) | 2008-04-25 | 2009-10-29 | Northwestern University | Nanostructures suitable for sequestering cholesterol and other molecules |
PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
EA028860B1 (ru) | 2009-06-10 | 2018-01-31 | Арбутус Биофарма Корпорэйшн | Улучшенная липидная композиция |
AU2012207606B2 (en) | 2011-01-11 | 2017-02-23 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
EP3434774A1 (de) | 2013-01-17 | 2019-01-30 | ModernaTX, Inc. | Signal-sensor-polynukleotide zur veränderung zellulärer phänotypen |
WO2014164253A1 (en) | 2013-03-09 | 2014-10-09 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
EP3556353A3 (de) | 2014-02-25 | 2020-03-18 | Merck Sharp & Dohme Corp. | Lipidnanopartikel-impfstoffadjuvanzien und antigenfreisetzungssysteme |
WO2017066797A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Trinucleotide mrna cap analogs |
CA3024917A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Combinations of mrnas encoding immune modulating polypeptides and uses thereof |
AU2019337637A1 (en) * | 2018-09-13 | 2021-04-22 | Modernatx, Inc. | Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease |
JP2022500444A (ja) * | 2018-09-14 | 2022-01-04 | モダーナティエックス・インコーポレイテッドModernaTX, Inc. | クリグラー−ナジャー症候群の治療のためのウリジン二リン酸グリコシルトランスフェラーゼ1ファミリー、ポリペプチドa1をコードするポリヌクレオチド |
AU2021205337A1 (en) * | 2020-01-10 | 2022-07-21 | Modernatx, Inc. | Methods of making tolerogenic dendritic cells |
EP4096720A2 (de) * | 2020-01-30 | 2022-12-07 | ModernaTX, Inc. | Für metabolische umprogrammierungspolypeptide codierende mrnas und deren verwendungen |
-
2021
- 2021-06-23 JP JP2022579691A patent/JP2023531511A/ja active Pending
- 2021-06-23 AU AU2021297248A patent/AU2021297248A1/en active Pending
- 2021-06-23 CN CN202180051902.6A patent/CN116194151A/zh active Pending
- 2021-06-23 MX MX2022016550A patent/MX2022016550A/es unknown
- 2021-06-23 KR KR1020237000782A patent/KR20230042005A/ko unknown
- 2021-06-23 BR BR112022025991A patent/BR112022025991A2/pt unknown
- 2021-06-23 US US18/012,094 patent/US20230242908A1/en active Pending
- 2021-06-23 CA CA3187261A patent/CA3187261A1/en active Pending
- 2021-06-23 IL IL299196A patent/IL299196A/en unknown
- 2021-06-23 WO PCT/US2021/038780 patent/WO2021262909A2/en unknown
- 2021-06-23 EP EP21748991.3A patent/EP4168556A2/de active Pending